Vial CRO provides oncology CRO Services to sponsors of all sizes. They are experts in oncology and have the expertise necessary to ensure the success of your cancer clinical trials. Read what’s more about their capabilities and experience. We will also discuss the different types of Oncology CRO Services available.
Vial CRO – Oncology CRO Services
Vial has add to its already impressive roster of scientific advisors in oncology by hiring Dr. Antoni Ribas, a pioneer of immuno-oncology. He will serve on Vial’s new Scientific Advisory Board, helping to establish the company’s CRO services in the field of oncology.
Vial’s new division will focus on cancer, adding to the company’s existing dermatology and ophthalmology CRO services. The new unit will offer faster execution for oncology sponsors. It will also utilize Vial’s eSource and ePRO systems to provide services for cancer trials.
Vial is excite to welcome Dr. Agarwal to its Scientific Advisory Board, and he will bring his clinical trial expertise to the company. Vial’s mission is to reimagine clinical trials for oncology sponsors by offering them higher-quality, faster trials. Vial has work with oncology sponsors to understand their specific pain points and designe its technology and processes to meet their needs.
Vial’s executive team is led by Betsey Zbyszynski, Head of Clinical Operations, Jason Shuris, Head of Sales, and Janet DuBois, MD, Medical Director. Together, this executive team has more than 100 years of experience in clinical trials in dermatology. Vial’s network of over 35 clinics is capable of running trials from Phase I to Phase IV in a timely manner.
BioDuro – Oncology CRO Services
BioDuro is a global contract research organization (CRO) specializing in pharmaceutical research and development. Its business model focuses on integrated drug discovery, biopharmaceutical synthesis, formulation, and cGMP manufacturing of drug products. The company was founded in 2005 and is led by Dr. Masood Tayebi, its Chairman.
BioDuro’s services are integrated across key disciplines in addition in vitro and in vivo oncology, chemistry, biology, and computer aided drug discovery. Additionally, BioDuro provides comprehensive clinical trial materials preparation. BioDuro also offers in vitro and animal tests to ensure safety and effectiveness.
BioDuro is headquartered in San Diego, California and has locations in Beijing and Shanghai. Its integrated drug discovery and development services span target identification, drug metabolism, and discovery biology. It is a member of the PPD organization and is able to leverage a vast library of assays for drug discovery.
BioDuro will expand its services globally
It plans to expand operations in China and expand its cGMP drug production facilities in San Diego. With the funding from Advent, BioDuro will accelerate its expansion plans and continue to expand its international business. The company’s board of directors will be led by David Preston and Amit Patel, who have extensive experience in the life sciences industry.
BioDuro is a hybrid CRO-CDMO that provides integrated project management and full development services. Its experienced team of research scientists, clinical experts, and executives brings a wealth of experience to the table. Its executives’ knowledge of the drug discovery process makes it the perfect partner for a large pharmaceutical client.
The company has been accredited by the US FDA and EMA. It is also certified by the Ministry of Health of China and has a strong history of compliance. Its latest IPO in Hong Kong and Series D financing round for small-molecule drugs. The company also has several drug candidates in its pipeline.
Catalyst Oncology CRO Services
Catalyst Oncology will be a fully-integrated oncology CRO, offering a network of 500 investigator sites and portfolio of more than 100 ongoing studies in the oncology therapeutic area. It also plans to incorporate Aptus’s site relationships and more than 800 staff members to provide comprehensive services for both clients and patients. The combined company will serve more than 5,300 patients with cancer and is ideally positioned to expand its portfolio and clinical research efforts.
Catalyst is actively building out its Early Phase Site Network, leveraging AI-based technologies that help better match patients with trials. This combination of expertise will help accelerate the execution of oncology clinical trials and enhance customer value. Aptus’ strategic site network is also a key asset for the new company, allowing it to better support its clients and accelerate global growth.
The merger will also enable Catalyst to provide more oncology-specific therapeutic expertise to biotechnology sponsors. Together, Catalyst and Ce3 will provide oncology clinical development services to the biotechnology industry. The combined company will retain a single headquarters in Wilmington, North Carolina, and another office in Clinton, Connecticut.
Precision for Medicine
Precision for Medicine is a leader in oncology CRO services, focusing on the development of cancer and rare disease therapies. With over 1800 experts in 30 offices worldwide, Precision for Medicine offers industry-leading operational expertise, biomarker solutions, and novel clinical trial designs. Our oncology CRO services are complemented by our scientific expertise and deep domain knowledge.
Read also: What is a CRO (Contract Research Organization)?
Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts in biomarker research and genomics. Their expertise extends beyond regulatory submission to launch strategies, payer insights, and specialty lab services. This comprehensive approach helps life sciences and pharmaceutical clients address the growing challenges of a fast-changing environment.
The company initially focuses on cancer
It has now branched out into other areas of healthcare. It has developed a suite of predictive algorithm laboratory-developed tests and has partnered with more than 40% of oncologists in the U.S. and 50% of academic medical centers. Its library of de-identified research records in addition more than 5 million patients. Its precision medicine software enables physicians to make near-real-time decisions about patients’ care.
Precision medicine, also known as personalized medicine, uses omics-based technologies, such as DNA, RNA, and protein analysis to better understand and treat patients with cancer. The advent of this new technology requires a new approach to clinical trials. The ability to use genetic information to guide drug treatment can lead to more effective therapies.
The precision of precision medicine is crucial to bringing effective treatments to patients. Precision for Medicine in Oncology CRO Services can help with the development of new treatments and cures. The company’s website is dedicated to oncology research and offers CME-accredited courses and resources. Precision for Medicine in Oncology is a global company with offices in the US, Europe, China, and Russia.
Theradex
If you are interested in working in the field of oncology, consider a career with oncology CRO services. This company provides a comprehensive range of clinical trial services. It offers a competitive salary and benefits package to its employees. In addition, it offers a flexible schedule and is an equal opportunity employer.
CRO services are tailore to meet the specific needs of research sponsors. In addition data management, clinical monitoring, regulatory consulting, statistical design, and statistical programming. Other services in addition medical writing and quality assurance. This company has a wealth of experience in oncology.
Theradex has more than 30 years of experience in managing and monitoring oncology clinical trials. Its expertise spans phase I to phase IV. Its experts ensure that a study is conducte according to the protocol, standards of practice, and applicable regulatory requirements. Furthermore, the team comprises scientifically trained personnel, with experience in the pharmaceutical industry and graduate degrees in relevant fields.
Theradex also provides safety services for cancer drug development. Its team of PvG experts has extensive experience in the field and can help companies implement a global compliant pharmacovigilance (PvG) system. Its fully electronic platform, TheradexTECH, is certify according to European Medicine Agency Guidelines and the International Conference of Harmonization.
Theradex has extensive experience in early phase clinical trials for the National Cancer Institute. Its CTMS program has audite and collecte data for many early-phase cancer trials, as well as for NCI-sponsore cancer center programs and national cooperative groups. Its expertise in the field of cancer treatment has led it to participate in a range of clinical trials and contribute to new anti-cancer therapies.
